文献速递认知障碍与痴呆

Tau蛋白阴性遗忘型痴呆酷似阿尔茨海默病痴呆

Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.
PubMed 文献 · Neurology · 2018-02-07

研究描述8例临床和影像学酷似阿尔茨海默病(AD)的Tau蛋白阴性遗忘型痴呆患者,所有患者均有海马萎缩,4例淀粉样蛋白阳性但全部Tau蛋白阴性;作者认为AD不太可能是其临床和神经退行性影像表现的原因,并强调AD研究中生物标志物的重要性。

要点

  • 8例遗忘型轻度认知障碍或AD痴呆患者中,4例淀粉样蛋白阳性(SUVR>1.42),全部Tau蛋白阴性(SUVR<1.33)。
  • 所有患者均有海马萎缩,2例低于老年对照AD特征厚度截断值(2.57),另3例低于年轻对照更严格截断值(2.67)。
  • 作者认为AD不太可能是这些患者临床和神经退行性影像表现的原因。

核心结论

  • 这些患者存在临床损害和结构性影像证据的神经退行性变,但无显著Tau蛋白沉积,因此AD不太可能是其临床表现和神经退行性影像发现的原因。

研究设计与样本

  • 8例遗忘型轻度认知障碍或AD痴呆患者由行为神经科医生评估并完成标准化神经心理学成套测验,所有患者完成结构MRI及淀粉样蛋白和Tau蛋白PET分子影像。

主要发现

  • 所有患者在PET成像前均被认为AD是症状的主要驱动因素。
  • 所有患者均有海马萎缩,2例低于基于老年对照的AD特征厚度截断值(2.57),另3例低于基于年轻对照的更严格截断值(2.67)。
  • 4例淀粉样蛋白阳性(SUVR>1.42),全部Tau蛋白阴性(SUVR<1.33)。

关键数值与推荐

  • 淀粉样蛋白阳性定义为SUVR>1.42,Tau蛋白阴性定义为SUVR<1.33。
  • AD特征厚度截断值:老年对照为2.57,年轻对照为2.67。

临床怎么用

  • 作者讨论了若干启示,包括在将N+参与者纳入AD疾病修饰治疗试验前,需先确立淀粉样蛋白和Tau蛋白阳性状态。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. METHODS: Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status. RESULTS: All participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33). CONCLUSIONS: The participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Botha H, Mantyh WG, Graff-Radford J, et al. Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology. 2018. PMID: 29438037. doi:10.1212/WNL.0000000000005124

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。